GSK PLC ADR (GSK) News

GSK PLC ADR (GSK): $33.60

-0.26 (-0.77%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

B

Add GSK to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals

Industry

D

Ranked

#8 of 167

in industry

Filter GSK News Items

GSK News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GSK News Highlights

  • For GSK, its 30 day story count is now at 21.
  • Over the past 14 days, the trend for GSK's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • DRUG, AGE and HEAR are the most mentioned tickers in articles about GSK.

Latest GSK News From Around the Web

Below are the latest news stories about GSK PLC that investors may wish to consider to help them evaluate GSK as an investment opportunity.

Top Pharmaceutical Stocks for Q2 2023

Aclaris Therapeutics, Collegium Pharmaceutical, and Intra-Cellular Therapies lead the industry in quarterly revenue growth

Yahoo | May 18, 2023

UPDATE 2-US FDA panel backs Pfizer's maternal RSV vaccine for protecting infants

Advisers to the U.S. Food and Drug Administration on Thursday backed the safety and effectiveness of Pfizer Inc's experimental respiratory syncytial virus (RSV) vaccine, boosting its chances of becoming the first available maternal shot to protect babies from the illness. The FDA's advisory committee voted unanimously that available data supported the vaccine's efficacy for giving the shot to women in their second or third trimesters of pregnancy to prevent lower respiratory tract infection and severe disease in infants up to 6 months of age. The expert panel voted 10-4 that the data also supports the safety of the vaccine for that patient population, paving the way for likely U.S. approval.

Yahoo | May 18, 2023

25 Most Prescribed Medication in the World

In this article, we will be taking a look at the 25 most prescribed medication in the world. To skip our detailed analysis, you can go directly to see the 10 most prescribed medication in the world. The advancements that the medical field has accomplished over the past century, and especially in recent decades, has […]

Yahoo | May 18, 2023

US FDA advisers to discuss Pfizer's maternal RSV vaccine

Advisers to the U.S. Food and Drug Administration on Thursday will discuss Pfizer Inc's experimental respiratory syncytial virus (RSV) vaccine intended to protect infants through six months of age when given to expectant mothers. An estimated 58,000 to 80,000 children under 5 years old are hospitalized due to RSV infection annually in the United States, according to government data. The agency's staff reviewers on Tuesday deemed the safety data for Pfizer's vaccine "generally favorable".

Yahoo | May 18, 2023

India's GlaxoSmithKline Pharma's pre-tax profit falls on govt pricing caps

India's GlaxoSmithKline Pharmaceuticals Ltd reported an 8.6% fall in its pre-tax profit for the fourth quarter on Wednesday, hurt by the government's curbs on pricing of some essential medicines. Consolidated profit before tax dropped to 1.90 billion rupees ($23.23 million) for the quarter ended March 31, from 2.08 billion rupees a year earlier, the Indian unit of UK's GSK Plc said in an exchange filing. Revenue from operations at the maker of Augmentin antibiotic and T-Bact ointment fell 2.7% to 7.87 billion rupees.

Yahoo | May 17, 2023

BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition

MONTREAL, May 16, 2023--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previousl

Yahoo | May 16, 2023

3 Personalized Medicine Stocks to Buy for Long-Time Returns

Personalized medicine is the future of medicine.

John Blankenhorn on InvestorPlace | May 15, 2023

UPDATE 3-US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute

The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.

Yahoo | May 15, 2023

US Supreme Court rejects Teva challenge to $235 million GSK award in patent dispute

The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.

Yahoo | May 15, 2023

These 3 Global Drug Stocks Have a Prescription for High Yields

Let's review three pharma companies based outside the U.S. that promise reasonable valuations and solid dividend yields.

Yahoo | May 13, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.8954 seconds.